PropertyValue
is ?:annotates of
?:authorAffiliation
  • [\'Department of Infectious Disease, Imperial College London, London, UK. minglee@doctors.org.uk.\', \'HIV i-Base, London, UK.\', \'Imperial Clinical Trials Unit, School of Public health, Imperial College London, London, UK.\', \'King\'s Clinical Trials Unit, King\'s College London, London, UK.\', \'NIHR Imperial Clinical Research Facility, Imperial College London, London, UK.\', \'Peter Medawar Building for Pathogen Research, University of Oxford, Oxford, UK.\', \'Department of Infectious Disease, Imperial College London, London, UK.\', \'Imperial College Clinical Trials Centre, Imperial College Healthcare NHS Trust, London, UK.\', \'Harrison Wing, Guy\'s and St Thomas Hospital NHS Foundation Trust, London, UK.\', \'Department of Medicine, University of California, San Francisco, CA, 94110, USA.\', \'Laboratory of Molecular Immunology, The Rockefeller University, New York, USA.\']
?:citedBy
  • -1
?:creator
?:doi
?:doi
  • 10.1186/s13063-022-06151-w
?:hasPublicationType
?:journal
  • Trials
is ?:pmid of
?:pmid
?:pmid
  • 35382844
?:publication_isRelatedTo_Disease
?:rankingScore_SJR
  • 1.291
?:rankingScore_hIndex
  • 57
?:title
  • The RIO trial: rationale, design, and the role of community involvement in a randomised placebo-controlled trial of antiretroviral therapy plus dual long-acting HIV-specific broadly neutralising antibodies (bNAbs) in participants diagnosed with recent HIV infection-study protocol for a two-stage randomised phase II trial.
?:type
?:year
  • 2022

Metadata

Anon_0  
expand all